Lefumide 10 mg Cipla
| Features | |
| Also known as | SU101, Arava |
| Blood pressure | Can cause hypertension |
| Chemical name | 5-methylisoxazole-4-carboxylic acid 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)butylamide |
| Dosage (medical) | Typically 100 mg daily for three days, then reduced to 10-20 mg daily |
| Dosage (sports) | Not applicable |
| Effects | Reduces inflammation and slows disease progression in rheumatoid arthritis and psoriatic arthritis |
| Formula | C12H9F3N2O2 |
| Half-life | Approximately 14-18 days |
| Hepatotoxicity | Yes, potential for significant liver injury, requires regular liver function tests |
| Lab Test | Liver function tests, complete blood count |
| Main action | Inhibits the mitochondrial enzyme dihydroorotate dehydrogenase, leading to a reduction in pyrimidine synthesis and modulation of the immune system |
| Side effects | Diarrhea, respiratory infections, hair loss, rash, hypertension, and liver toxicity |
| Storage conditions | Store at room temperature away from moisture and heat |
| Strength | 10 mg |
| Substance class | Disease-modifying antirheumatic drug (DMARD) |
| Trade name | Arava |
| Use in sports | None, as it is not performance-enhancing |
| Water Retention | Minimal to none |
| Manufacturer | Cipla |